| Issue Date | Title | Involved Person(s) |
| 2020 | Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg depression rating scale, the gold standard clinician rating scale : a meta-analysis of randomised placebo-controlled trials | Hengartner, Michael Pascal; Jakobsen, Janus C.; Sørensen, Anders; Plöderl, Martin |
| 24-Jun-2019 | Letter to the editor: newer-generation antidepressants and suicide risk in randomized controlled trials : a re-analysis of the FDA database | Hengartner, Michael Pascal; Plöderl, Martin |
| 2019 | Guidelines for the pharmacological acute treatment of major depression : conflicts with current evidence as demonstrated with the German S3-guidelines | Plöderl, Martin; Hengartner, Michael Pascal |
| 2019 | Reply to the letter to the editor : “newer-generation antidepressants and suicide risk : thoughts on Hengartner and Plöderl’s re-analysis” | Hengartner, Michael Pascal; Plöderl, Martin |
| 2019 | What are the chances for personalised treatment with antidepressants? : detection of patient-by-treatment interaction with a variance ratio meta-analysis | Plöderl, Martin; Hengartner, Michael Pascal |
| 2019 | Comment on Osler et al : misinterpretation of pre‐post‐differences invalidate the authors’ conclusions | Volkmann, Constantin; Plöderl, Martin; Hengartner, Michael Pascal |
| 2018 | Statistically significant antidepressant-placebo differences on subjective symptom-rating scales do not prove that the drugs work : effect Size and method bias matter! | Hengartner, Michael P.; Plöderl, Martin |
